208 related articles for article (PubMed ID: 27686857)
1. Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood.
Shatzer A; Ali MA; Chavez M; Dowdell K; Lee MJ; Tomita Y; El-Hariry I; Trepel JB; Proia DA; Cohen JI
Leuk Lymphoma; 2017 Apr; 58(4):923-931. PubMed ID: 27686857
[TBL] [Abstract][Full Text] [Related]
2. An EBNA3A-Mutated Epstein-Barr Virus Retains the Capacity for Lymphomagenesis in a Cord Blood-Humanized Mouse Model.
Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Zumwalde NA; Bristol JA; Nelson SE; Ma S; Ranheim EA; Gumperz JE; Johannsen EC; Kenney SC
J Virol; 2020 May; 94(10):. PubMed ID: 32132242
[TBL] [Abstract][Full Text] [Related]
3. Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation in vitro.
Kotsiopriftis M; Tanner JE; Alfieri C
J Virol; 2005 Jun; 79(11):7255-61. PubMed ID: 15890964
[TBL] [Abstract][Full Text] [Related]
4. Identification of IgH gene rearrangement and immunophenotype in an animal model of Epstein-Barr virus-associated lymphomas.
Zhang Y; Peng X; Tang Y; Gan X; Wang C; Xie L; Xie X; Gan R; Wu Y
J Med Virol; 2016 Oct; 88(10):1804-13. PubMed ID: 26991077
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas.
Kennedy G; Komano J; Sugden B
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14269-74. PubMed ID: 14603034
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.
Nikiforow S; Bottomly K; Miller G
J Virol; 2001 Apr; 75(8):3740-52. PubMed ID: 11264363
[TBL] [Abstract][Full Text] [Related]
7. Expression of LMP and EBNA genes in Epstein-Barr virus-associated lymphomas in Hu-PBL/SCID mice.
Tang Y; Lu S; Gan X; Liu F; Zhang Y; Luo C; Pan Y; Hong L; Gan R
Oncol Rep; 2016 Feb; 35(2):905-11. PubMed ID: 26548532
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 15-mediated induction of cytotoxic effector cells capable of eliminating Epstein-Barr virus-transformed/immortalized lymphocytes in culture.
Sharif-Askari E; Fawaz LM; Tran P; Ahmad A; Menezes J
J Natl Cancer Inst; 2001 Nov; 93(22):1724-32. PubMed ID: 11717333
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells.
Rasul AE; Nagy N; Sohlberg E; Ádori M; Claesson HE; Klein G; Klein E
J Immunol Methods; 2012 Nov; 385(1-2):60-70. PubMed ID: 22921685
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus B Cell Growth Transformation: The Nuclear Events.
Zhao B
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112815
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.
Coleman CB; Lang J; Sweet LA; Smith NA; Freed BM; Pan Z; Haverkos B; Pelanda R; Rochford R
J Virol; 2018 Nov; 92(21):. PubMed ID: 30089703
[TBL] [Abstract][Full Text] [Related]
12. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
13. EBNA-2 -deleted Epstein-Barr virus from P3HR-1 can infect rabbits with lower efficiency than prototype Epstein-Barr virus from B95-8.
Sano H; Nagata K; Kato K; Kanai K; Yamamoto K; Okuno K; Kuwamoto S; Higaki-Mori H; Sugihara H; Kato M; Murakami I; Kanzaki S; Hayashi K
Intervirology; 2013; 56(2):114-21. PubMed ID: 23295915
[TBL] [Abstract][Full Text] [Related]
14. An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model.
Romero-Masters JC; Ohashi M; Djavadian R; Eichelberg MR; Hayes M; Bristol JA; Ma S; Ranheim EA; Gumperz J; Johannsen EC; Kenney SC
PLoS Pathog; 2018 Aug; 14(8):e1007221. PubMed ID: 30125329
[TBL] [Abstract][Full Text] [Related]
15. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
[TBL] [Abstract][Full Text] [Related]
16. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
[TBL] [Abstract][Full Text] [Related]
17. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
18. Mouse model for acute Epstein-Barr virus infection.
Wirtz T; Weber T; Kracker S; Sommermann T; Rajewsky K; Yasuda T
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13821-13826. PubMed ID: 27856754
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus subverts mevalonate and fatty acid pathways to promote infected B-cell proliferation and survival.
Wang LW; Wang Z; Ersing I; Nobre L; Guo R; Jiang S; Trudeau S; Zhao B; Weekes MP; Gewurz BE
PLoS Pathog; 2019 Sep; 15(9):e1008030. PubMed ID: 31518366
[TBL] [Abstract][Full Text] [Related]
20. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.
Islas-Ohlmayer M; Padgett-Thomas A; Domiati-Saad R; Melkus MW; Cravens PD; Martin Mdel P; Netto G; Garcia JV
J Virol; 2004 Dec; 78(24):13891-900. PubMed ID: 15564497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
